LM Advisors
RPRX icon

LM Advisors’s Royalty Pharma RPRX Stock Holding History

LM Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,941
Closed -$909K – 230
2026
Q1 		$909K Buy
18,941
+1,262
+7% +$55.3K 0.13% 106
2025
Q4 		$683K Buy
+17,679
New +$674K 0.09% 119
2024
Q1 		– Sell
-369
Closed -$10.4K – 615
2023
Q4 		$10.4K Buy
+369
New +$10.1K ﹤0.01% 523

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LM Advisors's RPRX Position: Q2 2026 in Review

LM Advisors sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 18,941 shares — an estimated $909K sold.

LM Advisors first reported a position in RPRX in Q4 2023 and held it in 3 quarters. The position peaked at $909K in Q1 2026. 648 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • LM Advisors reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • LM Advisors sold 18,941 Royalty Pharma shares in Q2 2026, an estimated $909K.
  • LM Advisors first reported a position in Royalty Pharma in Q4 2023 and held it in 3 quarters.
  • LM Advisors's Royalty Pharma position peaked at $909K in Q1 2026.
  • 648 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on LM Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.